229 related articles for article (PubMed ID: 32714835)
1. Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy.
Hongo K; Harada T; Fukuro E; Kobayashi M; Ohashi T; Eto Y
Mol Genet Metab Rep; 2020 Sep; 24():100623. PubMed ID: 32714835
[TBL] [Abstract][Full Text] [Related]
2. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
CEN Case Rep; 2023 Dec; ():. PubMed ID: 38135868
[TBL] [Abstract][Full Text] [Related]
4. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
5. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
8. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
9. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
Taguchi A; Ishii S; Mikame M; Maruyama H
Mol Genet Metab Rep; 2023 Mar; 34():100952. PubMed ID: 36624895
[TBL] [Abstract][Full Text] [Related]
10. Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease.
Okada J; Hossain MA; Wu C; Miyajima T; Yanagisawa H; Akiyama K; Eto Y
Mol Genet Metab Rep; 2018 Mar; 14():68-72. PubMed ID: 29326878
[TBL] [Abstract][Full Text] [Related]
11. Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
Tsukimura T; Shiga T; Saito K; Ogawa Y; Sakuraba H; Togawa T
Mol Genet Metab Rep; 2021 Sep; 28():100773. PubMed ID: 34136356
[TBL] [Abstract][Full Text] [Related]
12. Generation of an
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Jun; 31():100871. PubMed ID: 35782611
[TBL] [Abstract][Full Text] [Related]
13. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
14. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
[TBL] [Abstract][Full Text] [Related]
15. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
16. 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.
Hung CL; Wu YW; Lin CC; Lai CH; Jyh-Ming Juang J; Chao TH; Kuo L; Sung KT; Wang CY; Wang CL; Chu CY; Yu WC; Hou CJ
Acta Cardiol Sin; 2021 Jul; 37(4):337-354. PubMed ID: 34257484
[TBL] [Abstract][Full Text] [Related]
17. Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease.
Kaneda T; Takeda M; Suematsu T; Yamamoto R; Takata M; Higashikata T; Ino H; Tsujibata A; Hayashi K; Fujino N; Kawashiri MA
J Cardiol Cases; 2018 May; 17(5):178-181. PubMed ID: 30279886
[TBL] [Abstract][Full Text] [Related]
18. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
19. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J; Weidemann F
Curr Med Chem; 2018; 25(13):1530-1537. PubMed ID: 28618999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
